NCT02425566View on ClinicalTrials.gov

Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Hypertension
Interventions
DRUG

Trimethaphan

Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.

DRUG

Nitroglycerin

Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.

Trial Locations (1)

37232

Autonomic Dysfunction Center, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER